Veliparib + Placebo + Modified FOLFIRI + FOLFIRI + Bevacizumab + Fluorouracil infusion
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Untreated Metastatic Colorectal Cancer
Conditions
Untreated Metastatic Colorectal Cancer
Trial Timeline
Dec 2, 2014 → Sep 22, 2017
NCT ID
NCT02305758About Veliparib + Placebo + Modified FOLFIRI + FOLFIRI + Bevacizumab + Fluorouracil infusion
Veliparib + Placebo + Modified FOLFIRI + FOLFIRI + Bevacizumab + Fluorouracil infusion is a phase 2 stage product being developed by AbbVie for Untreated Metastatic Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02305758. Target conditions include Untreated Metastatic Colorectal Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02305758 | Phase 2 | Completed |
Competing Products
15 competing products in Untreated Metastatic Colorectal Cancer